High Grade B-Cell Lymphoma Burkitt-Like Lymphoma Recurrent

High grade B-cell lymphoma with Burkitt-like features that has returned after treatment presents one of the most challenging situations in cancer care, with survival outcomes that remain difficult to predict despite advances in understanding these aggressive blood cancers.

Table of contents

• What is High Grade B-Cell Lymphoma Burkitt-Like?
• Understanding Recurrent Disease
• Relationship to Burkitt Lymphoma
• Diagnosis and Testing
• Outlook for Recurrent Disease
• Treatment Approaches
• Challenges in Management

What is High Grade B-Cell Lymphoma Burkitt-Like?

High grade B-cell lymphoma is an aggressive form of non-Hodgkin lymphoma (a type of cancer that starts in white blood cells called lymphocytes). This disease affects the immune system, specifically a type of white blood cell known as B lymphocytes or B cells. When these cells become cancerous, they multiply rapidly and can form tumors in different parts of the body^[1].

The term “Burkitt-like” refers to lymphomas that share features with Burkitt lymphoma but don’t meet all the specific requirements for that diagnosis. These cancers can be very similar in appearance under a microscope and behave in a similarly aggressive manner. In 2016, the World Health Organization created a specific category for these diseases called high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, reflecting their distinct genetic characteristics^[5].

High grade B-cell lymphoma with Burkitt-like features is one of the most aggressive cancers that exists, with rapid growth patterns. If left untreated, it can be fatal in a short period of time^[8].

Understanding Recurrent Disease

When high grade B-cell lymphoma with Burkitt-like features is described as “recurrent,” it means the cancer has come back after initial treatment. Despite excellent results with first-line therapy, particularly in children, recurrent disease remains a major therapeutic challenge with poor outcomes^[6].

The outlook for patients with recurrent disease is very poor. Survival rates range from less than 10% to between 30% and 40%, with longer survival observed only in patients who receive a transplant. Because of the limited data available, which mostly comes from small groups of patients with different characteristics and treatments, it is currently impossible to determine the best treatment approach for this difficult-to-treat group^[6].

Most relapses occur within the first two years after completing therapy. Once the disease returns, it becomes much more difficult to achieve lasting control^[12].

Relationship to Burkitt Lymphoma

Understanding the connection between Burkitt-like lymphoma and Burkitt lymphoma is important for proper diagnosis and treatment. Burkitt lymphoma is defined by a specific genetic change called a translocation involving the MYC gene. This genetic rearrangement causes the cancer cells to grow very rapidly^[3].

In adults, high grade B-cell lymphoma with Burkitt-like features is often very difficult to distinguish from both Burkitt lymphoma and another aggressive cancer called diffuse large B-cell lymphoma. Accurate diagnosis is critical because each of these diseases requires different treatment approaches. For this reason, experts strongly recommend that patients seek evaluation from specialists with expertise in lymphoma^[3].

High grade B-cell lymphoma may share genetic features with both diffuse large B-cell lymphoma and Burkitt lymphoma. About 5% of diffuse large B-cell lymphomas and about 32% to 78% of Burkitt lymphomas have rearrangements of both the MYC gene and either the BCL2 or BCL6 genes, which places them in the high grade B-cell lymphoma category^[5].

Some high grade B-cell lymphomas have features that appear similar to Burkitt lymphoma under the microscope but don’t meet all the criteria for a Burkitt lymphoma diagnosis. These cases require specialized testing to determine the correct classification^[20].

Diagnosis and Testing

Diagnosis of high grade B-cell lymphoma with Burkitt-like features requires several types of tests. The process often begins with a physical examination to check for swollen lymph nodes and a neurological exam to test how well the brain and nerves are working^[13].

Blood tests are an important part of diagnosis. These can sometimes show whether lymphoma cells are present in the bloodstream. Blood tests also measure levels of an enzyme called lactate dehydrogenase (LDH), which is often elevated in people with lymphoma. Additional blood tests may check for infections that increase the risk of certain types of lymphoma^[13].

Imaging tests create pictures of the body to show the location and extent of the disease. These may include CT scans (computed tomography) and PET scans (positron emission tomography). If doctors suspect the cancer affects the central nervous system (the brain and spinal cord), they may also perform an MRI scan^[13].

A biopsy is a critical procedure where doctors remove a sample of tissue for examination in a laboratory. For lymphoma diagnosis, this often involves removing all or part of a lymph node. Laboratory tests on the biopsy sample can confirm whether high grade B-cell lymphoma is present and help determine its specific characteristics^[13].

Molecular tests that examine genes and chromosomes under a microscope are used to check for specific genetic rearrangements. These tests are essential for confirming a diagnosis of high grade B-cell lymphoma and distinguishing it from other similar diseases^[5].

Bone marrow aspiration and biopsy may also be performed. These procedures collect samples from the soft matter inside bones where blood cells are made. A needle draws liquid from the bone marrow (aspiration) and collects a small amount of solid tissue (biopsy). These samples help determine if the lymphoma has spread to the bone marrow^[13].

Outlook for Recurrent Disease

The prognosis for high grade B-cell lymphoma with Burkitt-like features that has recurred is generally poor. While initial treatment can cure many patients, those whose disease returns face significant challenges^[6].

Despite excellent cure rates in first-line therapy, particularly in children who may achieve cure rates exceeding 90%, and in adults who may reach 70%, recurrent disease remains a major problem. When the disease comes back, outcomes are much worse, with survival rates dropping dramatically^[6].

Patients who undergo stem cell transplantation after their disease recurs tend to have longer survival times than those who receive only chemotherapy. However, even with transplantation, long-term survival remains challenging^[6].

The very aggressive nature of these cancers means they grow and spread quickly. This rapid progression makes treatment more difficult once the disease has returned, as the cancer cells may have developed resistance to the medications used in initial treatment^[8].

Treatment Approaches

Treatment for recurrent high grade B-cell lymphoma with Burkitt-like features is complex and requires specialized care. Chemotherapy remains the main treatment approach, though the specific regimens used may differ from initial treatment^[11].

Several different chemotherapy combinations have been used for recurrent disease. These intensive treatment regimens aim to kill cancer cells throughout the body. Because of the aggressive nature of these lymphomas, treatment often requires hospitalization to monitor for complications^[11].

Hematopoietic stem cell transplantation (also called bone marrow transplant) may be considered for eligible patients whose disease has recurred. This treatment involves giving high doses of chemotherapy to destroy cancer cells, followed by transplantation of healthy stem cells to rebuild the blood and immune system. This approach offers the best chance for longer survival in patients with recurrent disease^[6].

New insights into how these cancer cells work have led to the development of targeted therapies directed at specific features of the cancer cells. These newer drugs are currently being tested in clinical trials to see if they can improve outcomes for patients with recurrent disease^[6].

Supportive care is an essential part of treatment. This includes antibiotics for infections that may occur when the immune system is weakened by treatment, growth factors to help the body produce more blood cells, and transfusions of red blood cells or platelets as needed^[11].

Clinical trials may offer access to promising new treatments that are not yet widely available. Healthcare professionals often encourage eligible patients to consider participating in clinical trials, as this can provide access to cutting-edge therapies while also contributing to medical knowledge^[11].

Challenges in Management

Managing recurrent high grade B-cell lymphoma with Burkitt-like features presents multiple challenges. The limited amount of available data makes it difficult to establish clear treatment guidelines. Most information comes from small studies of patients with varying characteristics, making it hard to draw firm conclusions about the best approach^[6].

One major challenge is that older patients or those with multiple other health conditions may not be able to tolerate the highly intensive chemotherapy regimens that offer the best chance of controlling the disease. These patients require careful assessment to find a balance between treatment effectiveness and safety^[6].

The risk of serious complications during treatment is significant. Tumor lysis syndrome, a condition that occurs when cancer cells die rapidly and release their contents into the bloodstream, is a particular concern. This can cause dangerous changes in blood chemistry that affect the kidneys and heart. Patients require close monitoring and preventive measures during treatment^[11].

Another challenge is the potential for the lymphoma to spread to the central nervous system. This can cause serious complications and requires specific treatment approaches. Some treatment regimens include medications specifically designed to prevent or treat central nervous system involvement^[15].

The heterogeneous nature of high grade B-cell lymphoma with Burkitt-like features means that different patients may have tumors with different characteristics. This variability makes it difficult to develop one treatment approach that works well for everyone. Ongoing research aims to better understand these differences and develop more personalized treatment strategies^[5].